Maravai LifeSciences (NASDAQ:MRVI) Shares Gap Down - Here's Why

Key Points

• Maravai LifeSciences shares fell at the open, declining from a previous close of $8.37 to $8.12 and last trading near $8.09 on volume of about 550,000 shares.
• Analyst views remain mixed: UBS and Weiss Ratings maintain negative ratings, while Deutsche Bank and Wells Fargo are more positive. The overall consensus is “Hold,” with a $6.25 price target—below the stock’s recent trading level.
• The company exceeded quarterly expectations, reporting a loss of $0.02 per share versus the expected $0.04 loss and revenue of $51.44 million versus the $48.67 million consensus estimate, though it remains unprofitable with a negative net margin.

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) gapped down prior to trading on Friday . The stock had previously closed at $8.37, but opened at $8.12. Maravai LifeSciences shares last traded at $8.09, with a volume of 549,954 shares trading hands.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on MRVI. UBS Group reissued a "reduce" rating on shares of Maravai LifeSciences in a report on Wednesday, June 3rd. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and set a $6.00 price objective on shares of Maravai LifeSciences in a research report on Friday, May 8th. Weiss Ratings reissued a "sell (d-)" rating on shares of Maravai LifeSciences in a research note on Wednesday. Wells Fargo & Company upped their target price on shares of Maravai LifeSciences from $5.50 to $6.50 and gave the company an "overweight" rating in a report on Friday, August 7th. Finally, Wall Street Zen upgraded shares of Maravai LifeSciences from a "hold" rating to a "buy" rating in a report on Saturday, August 15th. Two research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company's stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $6.25.

Maravai LifeSciences Stock Performance

The firm has a market cap of $2.09 billion, a PE ratio of -15.48 and a beta of 0.63. The company has a debt-to-equity ratio of 0.49, a current ratio of 4.05 and a quick ratio of 2.98. The stock has a 50-day moving average price of $6.57 and a 200 day moving average price of $4.74.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.02. The firm had revenue of $51.44 million for the quarter, compared to the consensus estimate of $48.67 million. Maravai LifeSciences had a negative return on equity of 15.70% and a negative net margin of 37.07%. Research analysts forecast that Maravai LifeSciences Holdings, Inc. will post -0.2 earnings per share for the current year.

Insider Buying and Selling

In related news, General Counsel Kurt Oreshack sold 25,000 shares of the company's stock in a transaction that occurred on Tuesday, June 9th. The shares were sold at an average price of $5.06, for a total transaction of $126,500.00. Following the completion of the transaction, the general counsel owned 360,767 shares of the company's stock, valued at approximately $1,825,481.02. This represents a 6.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 2.49% of the company's stock.

Hedge Funds Weigh In On Maravai LifeSciences

A number of hedge funds have recently made changes to their positions in the stock. California State Teachers Retirement System raised its position in shares of Maravai LifeSciences by 61.5% in the 2nd quarter. California State Teachers Retirement System now owns 9,553 shares of the company's stock worth $60,000 after buying an additional 3,639 shares during the period. Headlands Technologies LLC purchased a new stake in shares of Maravai LifeSciences during the 2nd quarter worth about $1,038,000. Public Employees Retirement System of Ohio acquired a new stake in Maravai LifeSciences during the 2nd quarter worth approximately $728,000. Bank of New York Mellon Corp acquired a new position in Maravai LifeSciences during the second quarter valued at approximately $2,230,000. Finally, Royal Bank of Canada increased its position in shares of Maravai LifeSciences by 49.0% in the first quarter. Royal Bank of Canada now owns 9,761 shares of the company's stock worth $27,000 after acquiring an additional 3,209 shares in the last quarter. Institutional investors and hedge funds own 50.25% of the company's stock.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc NASDAQ: MRVI is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company's offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai's platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source